CAPLYTA is a once-daily capsule that is proven to help control symptoms of schizophrenia.
In 2 studies, people who took Caplyta showed:
CAPLYTA was significantly better than sugar pill (placebo) at managing schizophrenia symptoms
Improved overall severity
People taking CAPLYTA showed an improvement in the overall severity of their condition, measured on a schizophrenia rating scale
How CAPLYTA may work
Although the physical cause of schizophrenia is unknown, it is believed that imbalances between chemicals in the brain is the cause.
These chemicals, known as "neurotransmitters," are dopamine, serotonin, and glutamate. Schizophrenia can result from abnormal interactions among these neurotransmitters.
Schizophrenia is complicated. Although the exact way CAPLYTA works is unknown, it is thought to affect different brain-signaling chemicals to help control schizophrenia symptoms.
Watch the video below to learn more about how CAPLYTA may work in the brain.
Schizophrenia affects about 2.4 million Americans.1
It’s a serious disease that can make living a normal life a big challenge.2
People experience the symptoms of schizophrenia when certain naturally occurring chemicals in the brain go out of balance.
Two of these chemicals are serotonin and dopamine.1,2 Scientists think that restoring the right balance of serotonin and dopamine may help treat the symptoms of schizophrenia.1
CAPLYTA is a medicine for the treatment of schizophrenia in adults.
CAPLYTA could help treat symptoms of schizophrenia by adjusting serotonin and dopamine levels in the brain.
Like all medications used to treat schizophrenia, exactly how CAPLYTA works is unknown.
Medicines like CAPLYTA can raise the risk of death in elderly people with dementia-related psychosis who have lost touch with reality due to confusion and memory loss. CAPLYTA is not approved for treating people with dementia-related psychosis.
- CAPLYTA [prescribing information]. New York, NY: Intra-Cellular Therapies; December 2019.
- Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 1993;8(4):315-336.
- National Institutes of Health. Schizophrenia. Updated June 30, 2018. Accessed January 23, 2020. https://archives.nih.gov/asites/report/09-09-2019/report.nih.gov/nihfactsheets/ViewFactSheete76f.html?csid=67&key=S#
- Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. New York, NY: Cambridge University Press; 2013.